Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD123 CAR-T in R/R CD123+ AML
NCT04014881Phase 1Unknown
- Start
- Jul 2019
- Primary completion
- Jul 2021
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CD123 CAR-T cells in acute myeloid leukemia (AML). Primary endpoint: Incidence of Treatment-related Adverse Events at 3 years. Status: unknown.
02
Drugs
anti-CD123 CAR-T cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04014881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04014881.